PKCε deficits in Alzheimer's disease brains and skin fibroblasts

Journal of Alzheimer's Disease

Volumn 43, Issue 2, 2015, Pages 491-509

  Khan, Tapan K ^a   Sen, Abhik ^a   Hongpaisan, Jarin ^a   Lim, Chol S ^a   Nelson, Thomas J ^a   Alkon, Daniel L ^a  

^a Blanchette Rockefeller Neurosciences Institute   (United States)

Author keywords

Alzheimer's disease; amyloid oligomers; diagnostic assay; peripheral biomarker; PKC

Indexed keywords

AMYLOID BETA PROTEIN; OLIGOMER; PROTEIN KINASE C EPSILON; MESSENGER RNA; PROTEIN KINASE C;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; BRAIN; CLINICAL ARTICLE; CONTROLLED STUDY; DEMENTIA; FEMALE; HIPPOCAMPAL CA1 REGION; HIPPOCAMPUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PYRAMIDAL NERVE CELL; SKIN FIBROBLAST; TEMPORAL LOBE; ANALYSIS OF VARIANCE; CELL CULTURE; DEFICIENCY; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYMOLOGY; FIBROBLAST; GENETICS; METABOLISM; PATHOLOGY; SKIN; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANALYSIS OF VARIANCE; AUTOPSY; BRAIN; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLASTS; HUMANS; MALE; MIDDLE AGED; PROTEIN KINASE C; RNA, MESSENGER; SKIN;

EID: 84911924808     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-141221     Document Type: Article

References (38)

1. Mangialasche F, Solomon A, Winblad B, Mecocci P, KivipeltoM (2010) Alzheimer's disease: Clinical trials and drug development. Lancet Neurol 9, 702-716.
2. Coleman P, Federoff H, Kurlan R (2004) A focus on thesynapse for neuroprotection in Alzheimer disease and otherdementias. Neurology 63, 1155-1162.
3. Scheff SW, Price DA, Schmitt FA, Mufson EJ (2006) Hippocampalsynaptic loss in early Alzheimer's disease and mildcognitive impairment. Neurobiol Aging 27, 1372-1384.
4. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R (1991) Physical basis ofcognitive alterations in Alzheimer's disease: Synaptic loss isthe major correlate of cognitive impairment. Ann Neurol 30, 572-580.
5. Wetsel WC, Khan WA, Merchenthaler I, Rivera H, Halpern AE, Phung HM, Negro-Vilar A, Hannun YA (1992) Tissueand cellular distribution of the extended family of ProteinKinase C isoenzymes. J Cell Biol 117, 121-133.
6. Alkon DL, Sun MK, Nelson TJ (2007) PKCsignaling deficits:A mechanistic hypothesis for the origins of Alzheimer's disease. Trends Pharmacol Sci 28, 51-60.
7. Nelson TJ, Cui C, Luo Y, Alkon DL (2009) Reduction of betaamyloidlevels by novel protein kinase C (epsilon) activators. J Biol Chem 284, 34514-34521.
8. Hongpaisan J, Sun MK, Alkon DL (2011) PKC-activationprevents synaptic loss, A-elevation, and cognitive deficits inAlzheimer's disease transgenic mice. J Neurosci 31, 630-643.
9. Lee W, Boo JH, Jung MW, Park SD, Kim YH, Kim SU, Mook-Jung I (2004) Amyloid-peptide directly inhibits PKCactivation. Mol Cell Neurosci 26, 222-231.
10. Hongpaisan J, Xu C, Sen A, Nelson TJ, AlkonDL (2013) PKCactivation during training restores mushroom spine synapsesand memory in the aged rat. Neurobiol Dis 55, 44-62.
11. Choi DS, Wang D, Yu GQ, Zhu G, Kharazia VN, Paredes JP, Chang WS, Deitchman JK, Mucke L, Messing RO (2006) PKCepsilon increases endothelin converting enzyme activityand reduces amyloid plaque pathology in transgenic mice. Proc Natl Acad Sci USA 103, 8215-8220.
12. Lanni C, Mazzucchelli M, Porrello E, Govoni S, Racchi M (2004) Differential involvement of protein kinase C alpha andepsilon in the regulated secretion of soluble amyloid precursorprotein. Eur J Biochem 271, 3068-3075.
13. Etcheberrigaray R, Tan M, Dewachter I, Kuipéri C, Van derAuwera I, Wera S, Qiao L, Bank B, Nelson TJ, Kozikowski AP, Van Leuven F, Alkon DL (2004) Therapeutic effects ofPKC activators in Alzheimer's disease transgenic mice. Proc Natl Acad Sci USA 101, 11141-11146.
14. TakashimaA (2006) GSK-3 is essential in the pathogenesis ofAlzheimer's disease. J Alzheimers Dis 9(3 Suppl.) , 309-317.
15. Olds JL, Anderson ML, McPhie DL, Staten LD, Alkon DL (1989) Imaging of memory-specific changes in the distributionof protein kinase C in the hippocampus. Science 245, 866-869.
16. Sen A, Alkon DL, Nelson TJ (2012) Apolipoprotein E3(ApoE3) but not ApoE4 protects against synaptic loss throughincreased expression of protein kinase C epsilon. J Biol Chem 287, 15947-15958.
17. Citron M, Vigo-Pelfrey C, Teplow DB, Miller C, Schenk D, Johnston J, Winblad B, Venizelos N, Lannfelt L, SelkoeDJ (1994) Excessive production of amyloid beta-protein byperipheral cells of symptomatic and presymptomatic patientscarrying the Swedish familial Alzheimer disease mutation. Proc Natl Acad Sci USA 91, 11993-11997.
18. Eckert A, Cotman CW, Zerfass R, Hennerici M, Müller WE (1998) Lymphocytes as cell model to study apoptosis inAlzheimer's disease: Vulnerability to programmed cell deathappears to be altered. J Neural Transm Suppl 54, 259-267.
19. Goldstein LE, Muffat JA, Cherny RA, Moir RD, Ericsson MH, Huang X, Mavros C, Coccia JA, Faget KY, Fitch KA, Masters CL, Tanzi RE, Chylack LT Jr, Bush AI (2003) Cytosolic betaamyloiddeposition and supranuclear cataracts in lenses frompeople with Alzheimer's disease. Lancet 361, 1258-1265.
20. Joachim CL, Mori H, Selkoe DJ (1989) Amyloid beta-proteindeposition in tissues other than brain in Alzheimer's disease. Nature 341, 226-230.
21. Johnston JA, Cowburn RF, Norgren S, Wiehager B, Venizelos N, Winblad B, Vigo-Pelfrey C, Schenk D, Lannfelt L, O'NeillC (1994) Increased beta-amyloid release and levels of amyloidprecursor protein (APP) in fibroblast cell lines from familymembers with the Swedish Alzheimer's disease APP670/671mutation. FEBS Lett 354, 274-248.
22. Perry RH, Wilson ID, Bober MJ, Atack J, Blessed G, Tomlinson BE, Perry EK (1982) Plasma and erythrocyteacetylcholinesterase in senile dementia of Alzheimer type. Lancet 1, 174-175.
23. Scheuner D1, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, Larson E, Levy-Lahad E, Viitanen M, Peskind E, Poorkaj P, Schellenberg G, Tanzi R, Wasco W, Lannfelt L, Selkoe D, Younkin S (1996) Secreted amyloid beta-protein similar to that in thesenile plaques of Alzheimer's disease is increased in vivo bythe presenilin 1 and 2 and APP mutations linked to familialAlzheimer's disease. Nat Med 2, 864-870.
24. Sevush S, Jy W, Horstman LL, Mao WW, Kolodny L, Ahn YS (1998) Platelet activation in Alzheimer disease. Arch Neurol 55, 530-536.
25. Heinonen O, Soininen H, Syrjänen S, Neittaanmäki H, Paljärvi L, Kosunen O, Syrjänen K, Riekkinen P Sr (1992) Amyloid beta-protein deposition in skin of patients withdementia, Lancet 339, 245.
26. Bermejo-Pareja F, Antequera D, Vargas T, Molina JA, CarroE (2010) Saliva levels of A-42 as potential biomarker ofAlzheimer's disease: A pilot study. BMC Neurol 10, 108.
27. Khan TK, Alkon DL (2006) An internally controlled peripheralbiomarker for Alzheimer's disease: Erk1 and Erk2responses to the inflammatory signal bradykinin. Proc Natl Acad Sci USA 103, 13203-13207.
28. Zhao WQ, Ravindranath L, Mohamed AS, Zohar O, Chen GH, Lyketsos CG, Etcheberrigaray R, Alkon DL (2002) MAPkinase signaling cascade dysfunction specific to Alzheimer'sdisease in fibroblasts. Neurobiol Dis 11, 166-183.
29. Youmans KL, Tai LM, Kanekiyo T, Stine WB Jr, Michon SC, Nwabuisi-Heath E, Manelli AM, Fu Y, Riordan S, Eimer WA, Binder L, Bu G, Yu C, Hartley DM, LaDu MJ (2012) Intraneuronal A-detection in 5×FAD mice by a new A-specific antibody. Mol Neurodegener 7, 8.
30. Chen JQ, Heldman MR, Herrmann MA, Kedei N, Woo W, Blumberg PM, Goldsmith PK (2013) Absolute quantitationof endogenous proteins with precision and accuracy using acapillary Western system. Anal Biochem 442, 97-103.
31. Hoshi M, Sato M, Matsumoto S, Noguchi A, Yasutake K, Yoshida N, Sato K (2003) Spherical aggregates of-amyloid (amylospheroid) show high neurotoxicity and activate Tauprotein kinase I/glycogen synthase kinase-3-. Proc Natl Acad Sci USA 100, 6370-6375.
32. Noguchi A, Matsumura S, Dezawa M, Tada M, Yanazawa M, Ito A, Akioka M, Kikuchi S, Sato M, Ideno S, Noda M, Fukunari A, Muramatsu S, Itokazu Y, Sato K, Takahashi H, Teplow DB, Nabeshima Y, Kakita A, Imahori K, Hoshi M (2009) Isolation and characterization of patient-derived, toxic, high mass amyloid-protein (A-) assembly from Alzheimerdisease brains. J Biol Chem 284, 32895-32905.
33. Gross GG, Junge JA, Mora RJ (2013) Recombinant probes forvisualizing endogenous synaptic proteins in living neurons. Neuron 78, 971-985.
34. Briggs F, Mangun GR, UsreyWM (2013) Attention enhancessynaptic efficacy and the signal-to-noise ratio in neural circuits. Nature 499, 476-480.
35. Battaini F, Pascale A, Paoletti R, Govoni S (1997) The roleof anchoring protein RACK1 in PKC activation in the ageingrat brain. Trends Neurosci 20, 410-415.
36. Masliah E, Cole G, Shimohama S, Hansen L, DeTeresa R, Terry RD, Saitoh T (1990) Differential involvement of proteinkinase C isozymes in Alzheimer's disease. J Neurosci 10, 2113-2124.
37. Shimohama S, Narita M, Matsushima H, Kimura J, Kameyama M, Hagiwara M, Hidaka H, Taniguchi T (1993) Assessment of protein kinase C isozymes by two-site enzymeimmunoassay in human brains and changes in Alzheimer'sdisease. Neurology 43, 1407-1413.
38. Favit A, Grimaldi M, Nelson TJ, Alkon DL (1998) Alzheimer's-specific effects of soluble beta-amyloid on proteinkinase C-alpha and-gamma degradation in human fibroblasts. Proc Natl Acad Sci USA 95, 5562-5567.